Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of the National Cancer Institute

• Publication date

  2012-01-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jnci/djr500PMID 22228146PMCID PMC3260132
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New data on prostate-cancer mortality after PSA screening.

  2012cited by this paper
• Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results?

  2011cited by this paper
• Comorbidity and mortality results from a randomized prostate cancer screening trial.

  2011influential reference
• Screening and Prostate-Cancer Mortality in a Randomized European Study

  2010cited by this paper
• Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

  2010cited by this paper
• Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

  2010cited by this paper
• The effect of study arm on prostate cancer treatment in the large screening trial ERSPC

  2010cited by this paper
• Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials

  2010cited by this paper
• Utilization of surveillance colonoscopy in community practice.

  2010cited by this paper
• Prostate-cancer screening.

  2009cited by this paper
• Mortality results from a randomized prostate-cancer screening trial.

  2009cited by this paper
• Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

  2009cited by this paper
• Mortality Results from a Randomized ProstateCancer Screening Trial

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

  2009cited by this paper
• Studies of prostate-cancer mortality: caution advised.

  2008cited by this paper
• Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach

  2008cited by this paper
• Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.

  2007cited by this paper
• A population model of prostate cancer incidence

  2006cited by this paper
• Radical prostatectomy versus watchful waiting in early prostate cancer.

  2005cited by this paper
• Radical prostatectomy versus watchful waiting in early prostate cancer.

  2005cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• All-cause mortality in randomized trials of cancer screening.

  2002cited by this paper
• Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

  2000cited by this paper
• Biostatistics for Epidemiologists

  1993cited by this paper
• Screening for prostate cancer

  1993cited by this paper
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

  1987cited by this paper

• Identifying Predictive Combinations of Biomarkers for Early Cancer Detection with Stability Selection in Combination with Ensemble Learning

  2026cites this paper
• Target Trial Emulation for Regulatory and Clinical Decision Making in Cancer.

  2026cites this paper
• Prostate specific membrane antigen (PSMA) as a biomarker in early and localized advanced prostate cancer: a narrative review.

  2026cites this paper
• [Prostate cancer screening: Evaluation of general practitioners' practices in Hérault].

  2026cites this paper
• Harnessing genomics for early cancer detection, risk stratification and prevention.

  2026cites this paper
• The evolving role of PSA in prostate cancer screening: revisiting the evidence in the era of personalized medicine

  2026cites this paper
• Advanced cancer: a robust surrogate of cancer mortality in early detection trials?

  2025cites this paper
• Semiparametric Transformation Models with a Change Point for Interval-Censored Failure Time Data

  2025cites this paper
• Novel AI applications in systematic review: GPT-4 assisted data extraction, analysis, review of bias

  2025cites this paper
• The democratization of cancer screening, or a waste of valuable resources?

  2025cites this paper
• Clinical Reliability and Diagnostic Value of Digital Rectal Examination in the Detection of Prostate Cancer and Broader Clinical Practice: A Narrative Review

  2025cites this paper
• The Golgi apparatus as a strategic target in cancer: mechanisms, diagnosis and therapeutic opportunities

  2025cites this paper
• Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals

  2025cites this paper
• Assessment of a Polygenic Risk Score in Screening for Prostate Cancer

  2025cites this paper
• Association between grain intake and prostate-specific antigen: A cross-sectional study from US men

  2025cites this paper
• Estimating the Heritability of Longitudinal Rate-of-Change: Genetic Insights into PSA Velocity in Prostate Cancer-Free Individuals

  2025cites this paper
• Can Prostate Cancer Screening Reduce Mortality in Men Aged 75–79 Years? A Protocol for Target-trial Emulation

  2025cites this paper
• Lipid biomarkers of habitual alcohol intake and associations with pancreatic cancer risk.

  2025cites this paper
• Analysing and Predicting Radiologists’ Expertise Using Eye-Tracking Data: Insights for Diagnostic Decision-Making

  2025cites this paper
• The contemporary management of prostate cancer

  2025cites this paper
• Life Expectancy Predicted by Decision-Analytic Models Evaluating Screening for Prostate, Lung, Breast, and Colorectal Cancer: A Systematic Review Focusing on Competing Mortality Risks

  2025cites this paper
• Prostate cancer screening in the Middle East and North Africa: a cross-sectional study on current practices

  2025cites this paper
• Diagnostic value of CD138 and GATA3 in benign prostatic hyperplasia and prostate cancer

  2025cites this paper
• Estimating the causal treatment effect in multi-site current status data with the additive hazards model and neural networks

  2025cites this paper
• Prostate Cancer Screening: Evolution, Challenges, and Future Directions.

  2025cites this paper
• Pre-diagnostic serum concentrations of free light chains and risk of non-Hodgkin lymphoma in a population-based prospective study

  2025cites this paper
• Screening von Prostatakrebs mit einem polygenen Risikoscore

  2025cites this paper
• Development of Neural Networks for Deep Learning Provides Optimized Prostate Cancer Diagnosis along with Precise and Early Detection Capabilities

  2025cites this paper
• Impact of patients’ age and comorbidities on prostate cancer overdiagnosis in clinical practice

  2025cites this paper
• Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer

  2024cites this paper
• Perspectives of clinicians and screening candidates on shared decision-making in prostate cancer screening with the prostate-specific antigen (PSA) test: a qualitative study (PROSHADE study)

  2024cites this paper
• Prostate Cancer Early Detection in the European Union and UK.

  2024cites this paper
• Liquid-Biopsy Glycan Score Biomarker Accurately Indicates and Stratifies Primary and Metastatic Prostate Cancers.

  2024cites this paper
• Hot issues on Chinese expert consensus of prostate cancer management

  2024cites this paper
• A cross-sectional study of the association between depression and serum prostate-specific antigen (PSA) among U.S. males: national health and nutrition examination survey (NHANES), 2005–2010

  2024cites this paper
• Optimising Extracellular Vesicle Metabolomic Methodology for Prostate Cancer Biomarker Discovery

  2024cites this paper
• Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000–19: a retrospective, cross-sectional, population-based study

  2024cites this paper
• Additive Hazards Regression Analysis of Massive Interval-Censored Data via Data Splitting

  2024cites this paper
• Dépistage et diagnostic précoce des cancers chez les personnes vivant avec le VIH à l’ère des antirétroviraux : spécificités et enjeux

  2024cites this paper
• Physical activity, metabolites, and breast cancer associations

  2024cites this paper
• Transfer learning under the Cox model with interval‐censored data

  2024cites this paper
• Prostate-Specific Antigen Screening and Prostate Cancer Mortality: An Emulation of Target Trials in US Medicare

  2024cites this paper
• Oncological outcomes after radical prostatectomy of localized prostate cancer: stratified by magnetic resonance imaging and risk classification

  2024cites this paper
• PSA screening for prostate cancer in the United States: 30 years of controversy

  2024cites this paper
• Graphene oxide@chitosan for urinary sarcosine extraction in prostate cancer detection: Method development and adsorption isotherm studies

  2024cites this paper
• Multidimensional Healthcare Access Barriers to Prostate‐Specific Antigen Testing: A Nation‐Wide Panel Study in the United States From 2006 to 2020

  2024cites this paper
• Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review

  2024cites this paper
• Deep Survival Models Can Improve Long-Term Mortality Risk Estimates from Chest Radiographs

  2024cites this paper
• Prostate cancer incidence rates, trends, and treatment related to prostate-specific antigen screening recommendations in the United States.

  2024cites this paper
• The Influence of Disparities on Prostate Cancer at Diagnosis in the Charlotte Metropolitan Area

  2024cites this paper
• ASSESSING SCREENING EFFICACY IN THE PRESENCE OF CANCER OVERDIAGNOSIS.

  2024cites this paper
• Quality of Life Longitudinal Evaluation in Prostate Cancer Patients from Radiotherapy Start to 5 Years after IMRT-IGRT

  2024cites this paper
• Prostate cancer-derived extracellular vesicles metabolic biomarkers: Emerging roles for diagnosis and prognosis.

  2024cites this paper
• Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review

  2024cites this paper
• Prostate cancer screening in Switzerland: a literature review and consensus statement from the Swiss Society of Urology.

  2024cites this paper
• Incorporating Genetic Risk Into Prostate Cancer Care: Implications for Early Detection and Precision Oncology.

  2024cites this paper
• Effect of an Invitation or the Effect of Participation: What Should Randomized Controlled Trials of Cancer Screening Examine?

  2024cites this paper
• Determinants of receipt of prostate cancer screening among men living with HIV enrolled in an urban HIV Clinic in the United States over the period of 2000-2020.

  2024cites this paper
• Prediagnostic Prostate-specific Antigen Testing and Clinical Characteristics in Men with Lethal Prostate Cancer

  2024cites this paper
• Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era

  2024cites this paper
• Estimated Lifetime Gained With Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials.

  2023cites this paper
• Cell-free DNA approaches for cancer early detection and interception

  2023cites this paper
• A new approach to prostate cancer screening

  2023cites this paper
• Una nueva perspectiva en el cribado del cáncer de próstata

  2023cites this paper
• Racial Disparities in Prostate Cancer Screening: The Role of Shared Decision-Making.

  2023cites this paper
• Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial

  2023cites this paper
• Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer

  2023cites this paper
• A nested case‐control study of untargeted albumin adductomics and acute myeloid leukemia

  2023cites this paper
• Disparities Associated with Shared Decision-making in Prostate Cancer Screening.

  2023cites this paper
• Using “Age and Total-PSA” as the Main Indicators: The Results of Taizhou Integrated Prostate Screening (No 2)

  2023cites this paper
• Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews.

  2023cites this paper
• Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps

  2023cites this paper
• Dynamics of Medical Screening: A Simulation Model of PSA Screening for Early Detection of Prostate Cancer

  2023cites this paper
• Investigating the racial gap in prostate cancer screening with prostate-specific antigen among younger men from 2012 to 2020

  2023cites this paper
• NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.

  2023cites this paper
• Knowledge and Attitudes towards Prostate Cancer and Screening among Males in Limpopo Province, South Africa

  2023cites this paper
• Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers

  2023cites this paper
• Regional disparities of prostate cancer mortality in Ecuador: an examination of trends and correlates from 2004 to 2019

  2023cites this paper
• Plasma and urinary extracellular vesicles as a source of RNA biomarkers for prostate cancer in liquid biopsies

  2023cites this paper
• A Novel Blood Proteomic Signature for Prostate Cancer

  2023cites this paper
• Development and validation of open-source deep neural networks for comprehensive chest x-ray reading: a retrospective, multicentre study.

  2023cites this paper
• Variable Selection for Length-Biased and Interval-Censored Failure Time Data

  2023cites this paper
• Underlying Features of Prostate Cancer—Statistics, Risk Factors, and Emerging Methods for Its Diagnosis

  2023cites this paper
• Unknown Causes of Death in Cancer Patients

  2023cites this paper
• Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade.

  2023cites this paper
• Benefits and harms of prostate specific antigen testing according to Australian guidelines

  2023cites this paper
• Advancements and application of sustainable nanotechnology-based biomedical products in cancer therapeutics

  2023cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection Version 1 . 2022 —

  2022cites this paper
• Intérêt du dépistage du cancer de la prostate

  2022cites this paper
• Study Design Considerations for Trials to Evaluate Multi-Cancer Early Detection Assays for Clinical Utility.

  2022cites this paper
• The importance of long-term follow up of participants in clinical trials

  2022cites this paper
• Lipidomics and pancreatic cancer risk in two prospective studies

  2022cites this paper
• Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending

  2022cites this paper
• LncRNA Osilr9 coordinates promoter DNA demethylation and the intrachromosomal loop structure required for maintaining stem cell pluripotency.

  2022cites this paper
• Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.

  2022cites this paper
• Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update

  2022cites this paper
• Editorial Comment.

  2022cites this paper
• A flexible parametric approach for analyzing arbitrarily censored data that are potentially subject to left truncation under the proportional hazards model

  2022cites this paper
• Screening asymptomatic men for prostate cancer: A comparison of international guidelines on prostate-specific antigen testing

  2022cites this paper
• Interesse dello screening del cancro della prostata

  2022cites this paper